Abbvie-Header Abbvie-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Irvine School of Medicine

            • Development Update

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ketamine Hydrochloride

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 30, 2020

            Details:

            The research team showed that ketamine down-regulates NRG1 expression in PV inhibitory cells, resulting in sustained cortical disinhibition to enhance cortical plasticity in adult visual cortex.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PMC-403

            Therapeutic Area: Ophthalmology Product Name: PMC-403

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: PharmAbcine

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership September 21, 2020

            Details:

            Samsung will provide CDO services from cell line development, process development, cGMP clinical manufacturing to IND filing support for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular disorders.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bimatoprost

            Therapeutic Area: Ophthalmology Product Name: LL-BMT1

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 05, 2020

            Details:

            The expanded SAB will provide independent scientific review and guidance to the Company with regards to its R&D activities and product pipeline which includes company’s lead glaucoma asset as well as its products for dry eye, allergy, and other anterior segment conditions.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Collagen Ophthalmic Matrix

            Therapeutic Area: Ophthalmology Product Name: ABCcolla

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 24, 2020

            Details:

            ACRO has successfully performed world’s first canine corneal transplantation using ABCcolla® Collagen Ophthalmic Matrix.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OLX301D

            Therapeutic Area: Ophthalmology Product Name: OLX301D

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: OliX Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement June 16, 2020

            Details:

            Under the terms of the agreement, LGC will produce the active pharmaceutical ingredients for the preclinical and clinical study of OLX301D program, for the treatment of sub-retinal fibrosis and wet macular degeneration.